C-WORTHY: The beginning of the rise of elbasvir and grazoprevir for the treatment of hepatitis C genotype 1 mono and HIV co-infected patients

Dost Sarpel; Douglas T. Dieterich

doi:10.21037/atm.2016.09.22

C-WORTHY: The beginning of the rise of elbasvir and grazoprevir for the treatment of hepatitis C genotype 1 mono and HIV co-infected patients

Research output: Contribution to journal › Editorial

3 Scopus citations

Original language	English
Article number	S12
Journal	Annals of Translational Medicine
Volume	4
DOIs	https://doi.org/10.21037/atm.2016.09.22
State	Published - Oct 2016

Access to Document

10.21037/atm.2016.09.22

Cite this

@article{01e2635314bf49d5818a9bc107b21547,

title = "C-WORTHY: The beginning of the rise of elbasvir and grazoprevir for the treatment of hepatitis C genotype 1 mono and HIV co-infected patients",

author = "Dost Sarpel and Dieterich, \{Douglas T.\}",

year = "2016",

month = oct,

doi = "10.21037/atm.2016.09.22",

language = "English",

volume = "4",

journal = "Annals of Translational Medicine",

issn = "2305-5839",

publisher = "AME Publishing Company",

}

TY - JOUR

T1 - C-WORTHY

T2 - The beginning of the rise of elbasvir and grazoprevir for the treatment of hepatitis C genotype 1 mono and HIV co-infected patients

AU - Sarpel, Dost

AU - Dieterich, Douglas T.

PY - 2016/10

Y1 - 2016/10

UR - https://www.scopus.com/pages/publications/85011390799

U2 - 10.21037/atm.2016.09.22

DO - 10.21037/atm.2016.09.22

M3 - Editorial

AN - SCOPUS:85011390799

SN - 2305-5839

VL - 4

JO - Annals of Translational Medicine

JF - Annals of Translational Medicine

M1 - S12

ER -